替比夫定治疗对慢性乙型肝炎和肝硬化患者血清可溶性红细胞补体受体1的影响

目的观察慢性乙型肝炎（CHB）和肝硬化患者经替比夫定抗病毒治疗3、6个月后血清可溶性红细胞补体受体1（s CR1）的变化,探讨替比夫定治疗对于s CR1水平的的影响。方法选择2013年1-6月在兰州军区兰州总医院安宁分院就诊的HBe Ag阳性CHB、肝硬化患者57例,给予替比夫定抗病毒治疗,于治疗前和治疗后3、6个月抽静脉血,采用ELISA法检测s CR1。组内比较采用配对t检验。两组间比较采用独立样本t检验。结果替比夫定抗病毒治疗后,全部患者在治疗3、6个月时s CR1与对应的基线水平相比差异有统计学意义（t值分别为4.864、6.238,P值均〈0.05）。CHB患者和肝硬化患者s CR1...

Full description

Saved in:
Bibliographic Details
Published in临床肝胆病杂志 Vol. 32; no. 6; pp. 1118 - 1120
Main Author 王方 权作华 杨兴坤 寇俊峰 云升皓 蔡国芳 周新人
Format Journal Article
LanguageChinese
Published 兰州军区兰州总医院安宁分院感染科,兰州,730070%武威市医院口腔科,甘肃武威,733000 2016
Subjects
受体,补体
替比夫定
肝炎,乙型,慢性
肝硬化
肝炎,乙型,慢性
替比夫定
肝硬化
telbifvdine
受体,补体
receptors,complement
hepatitis B,chronic
liver cirrhosis
Online AccessGet full text
ISSN1001-5256
DOI10.3969/j.issn.1001-5256.2016.06.019

Cover

More Information
Summary:目的观察慢性乙型肝炎（CHB）和肝硬化患者经替比夫定抗病毒治疗3、6个月后血清可溶性红细胞补体受体1（s CR1）的变化,探讨替比夫定治疗对于s CR1水平的的影响。方法选择2013年1-6月在兰州军区兰州总医院安宁分院就诊的HBe Ag阳性CHB、肝硬化患者57例,给予替比夫定抗病毒治疗,于治疗前和治疗后3、6个月抽静脉血,采用ELISA法检测s CR1。组内比较采用配对t检验。两组间比较采用独立样本t检验。结果替比夫定抗病毒治疗后,全部患者在治疗3、6个月时s CR1与对应的基线水平相比差异有统计学意义（t值分别为4.864、6.238,P值均〈0.05）。CHB患者和肝硬化患者s CR1水平在治疗3、6个月时与对应的基线相比差异均有统计学意义（t值分别为3.425、5.468、4.047、7.378,P值均〈0.05）。CHB患者血清s CR1水平在基线、治疗3、6个月均较肝硬化患者低,但两组间各时间点相比差异均无统计学意义（P值均〉0.05）。结论 HBe Ag阳性CHB、肝硬化患者经替比夫定抗病毒治疗后血清s CR1水平显著下降。
Bibliography:Objective To investigate the changes in serum soluble complement receptor type 1 （sCR1） at 3 and 6 months after antiviral therapy with telbivudine in patients with chronic hepatitis B （CHB） or liver cirrhosis and the influence of tclhivudine on serum sCR1 level. Methods A total of 57 patients with HBeAg - positive CHB or liver cirrhosis were enrolled and given the antiviral therapy with telbivudine. Venous blood was eollected bctore treatment and at 3 and 6 months after treatment, and enzyme - linked immunosorbent assay was used to measure serum sCRI level. The paired t - test was used for comparison within one group. Results At 3 and 6 months after the antiviral treatment with telbivudine, the serum sCR1 level changed significantly compared with corresponding haseline values （t = 4. 864 and 6. 238, both P 〈 0.05）. The patients with CHB or liver cirrhosis showed significant changes in the serum sCR1 level at 3 and 6 months after treat- mcnt compared with corresponding baseline values （ t = 3. 425,5. 468,4. 04
ISSN:1001-5256
DOI:10.3969/j.issn.1001-5256.2016.06.019